- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Mankind Pharma promoters divest 1.6 percent stake worth Rs 1367 crore
New Delhi: Mankind Pharma promoters on Thursday divested a 1.62 per cent stake in the company for Rs 1,367 crore through open market transactions.
According to the block deal data available with the NSE, promoters Sheetal Arora, Puja Juneja, and Arjun Juneja offloaded a total of 64,89,534 shares in two tranches each, representing a 1.62 per cent stake in Mankind Pharma, on the NSE.
The shares were disposed of at an average price of Rs 2,107.35 apiece, taking the combined deal value to Rs 1,367.57 crore.
Through the latest transaction, the combined shareholding of promoter and promoter group entities have declined to 74.88 per cent stake from 76.50 per cent stakeholding (as of December quarter) in Mankind Pharma.
As per market regulations, all listed companies must maintain an minimum public shareholding of 25 per cent, while newly-listed firms are given three years to meet the requirement of 25 per cent public float.
Accordingly, after the stake sale, the company has complied with the norms with 25 per cent minimum public shareholding rules.
Meanwhile, SBI Mutual Fund (MF), Axis MF, Motilal Oswal MF, ICICI Prudential Life Insurance, New World Fund Inc, Morgan Stanley Asia Singapore, Monetary Authority of Singapore, Singapore Government, and International Monetary Fund, among others were the buyers.
On Thursday, shares of Mankind Pharma jumped 5.72 per cent to close at Rs 2,250 apiece on the NSE.
Last month, Mankind Pharma reported its consolidated net profit increased 55 per cent to Rs 460 crore for the third quarter ended December 2023.
The company had posted a net profit of Rs 296 crore in the October-December quarter of the last fiscal. Its revenue from operations rose to Rs 2,607 crore in the period under review from Rs 2,091 crore in the year-ago period.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story